Treatment options for advanced ameloblastoma in the era of precision medicine: A brief review.
Oral Oncol
; 146: 106585, 2023 11.
Article
in En
| MEDLINE
| ID: mdl-37816291
ABSTRACT
Although complete excision is the standard of care for ameloblastoma, a subset of recurrent and/or metastasizing ameloblastomas are difficult to treat surgically. Over the past decade, several recurrent mutations in the mitogen-activated protein kinase pathway genes have been identified in ameloblastoma, based on which the efficacy of targeted therapy has been investigated. However, most of the literature has focused on BRAF V600E mutations, the most common oncogenic mutations in ameloblastoma. Hence, this study aims to review the current knowledge of targetable genetic alterations in ameloblastoma from a broader perspective. In addition, the therapeutic potential of immunotherapy for ameloblastoma will be briefly discussed in the context of tumoral PD-L1 expression and the tumor immune microenvironment.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ameloblastoma
/
Jaw Neoplasms
Limits:
Humans
Language:
En
Journal:
Oral Oncol
Journal subject:
NEOPLASIAS
Year:
2023
Document type:
Article